Search Results - "Vici, P."

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden by Marinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D'Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., Barba, M., Carpano, S., Vici, P., Filetti, M., Giusti, R., Vecchione, A., Occhipinti, M., Gelibter, A., Botticelli, A., De Nicola, F., Ciuffreda, L., Goeman, F., Gallo, E., Visca, P., Pescarmona, E., Fanciulli, M., De Maria, R., Marchetti, P., Ciliberto, G., Maugeri-Saccà, M.

“…Immune checkpoint inhibitors (ICIs) have demonstrated significant overall survival (OS) benefit in lung adenocarcinoma (LUAD). Nevertheless, a remarkable…”
Get full text

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives by Krasniqi, E, Barchiesi, G, Pizzuti, L, Mazzotta, M, Venuti, A, Maugeri-Saccà, M, Sanguineti, G, Massimiani, G, Sergi, D, Carpano, S, Marchetti, P, Tomao, S, Gamucci, T, De Maria, R, Tomao, F, Natoli, C, Tinari, N, Ciliberto, G, Barba, M, Vici, P

“…Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents…”
Get full text

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients by Trevisan, B., Pepe, F. F., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Clivio, L., Torri, V., Cazzaniga, M. E.

“…Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and…”
Get full text

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma by Scalera, S., Ricciuti, B., Mazzotta, M., Calonaci, N., Alessi, J.V., Cipriani, L., Bon, G., Messina, B., Lamberti, G., Di Federico, A., Pecci, F., Milite, S., Krasniqi, E., Barba, M., Vici, P., Vecchione, A., De Nicola, F., Ciuffreda, L., Goeman, F., Fanciulli, M., Buglioni, S., Pescarmona, E., Sharma, B., Felt, K.D., Lindsay, J., Rodig, S.J., De Maria, R., Caravagna, G., Cappuzzo, F., Ciliberto, G., Awad, M.M., Maugeri-Saccà, M.

“…KEAP1 mutations have been associated with reduced survival in lung adenocarcinoma (LUAD) patients treated with immune checkpoint inhibitors (ICIs),…”
Get full text

Laparoscopic versus robotic radical hysterectomy after neoadjuvant chemotherapy in locally advanced cervical cancer: A case control study by Vizza, E, Corrado, G, Mancini, E, Vici, P, Sergi, D, Baiocco, E, Patrizi, L, Saltari, M, Pomati, G, Cutillo, G

“…Abstract Objective To compare the surgical outcome of robotic radical hysterectomy (RRH) versus laparoscopic radical hysterectomy (LRH) for the treatment of…”
Get full text

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies by Vici, P, Pizzuti, L, Mariani, L, Zampa, G, Santini, D, Di Lauro, L, Gamucci, T, Natoli, C, Marchetti, P, Barba, M, Maugeri-Saccà, M, Sergi, D, Tomao, F, Vizza, E, Di Filippo, S, Paolini, F, Curzio, G, Corrado, G, Michelotti, A, Sanguineti, G, Giordano, A, De Maria, R, Venuti, A

“…Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two…”
Get more information

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study by Cazzaniga, M.E., Pinotti, G., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Fiorentini, G., Fontana, A., Gambaro, A.R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Melegari, E., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M.G., Schintu, M.G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M.R., Vici, P., Clivio, L., Torri, V., Cicchiello, F., Riva, F., Vallini, I., Mazza, M., Bonfadini, C., Bordin, E., Canicattì, M., Cappuccio, F., Collovà, E., De Angelis, C., Desorte, R., Donati, S., Drudi, G., Galanti, D., Mocerino, C., Orlando, L., Pellegrino, B., Pizzuti, L., Ridolfi, C., Rocca, A., Sarti, D., Spagnoletti, I., Tinari, N., Vandone, A., Vizzini, L.

“…Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no…”
Get full text

The case study of The daughters of the Emperor Ferdinand I by Jakob Seisenegger, in Trento (Italy): analytical hygro-mechanical results as a support in risk assessment for technical interventions by Allegretti, O, Dionisi-Vici, P, Bontadi, J, Raffaelli, F

“…In this paper, a long-term monitoring experience on a panel painting, carried out using a whole set of analytical tools before the scheduled conservation…”
Get full text

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study by Cazzaniga, M. E., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Di Mauro, P., Cogliati, V., Capici, S., Clivio, L., Torri, V.

“…Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor…”
Get full text

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review by SWAIN, S. M, VICI, P

“…This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy…”
Get full text

MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study by Krasniqi, E, Sacconi, A, Marinelli, D, Pizzuti, L, Mazzotta, M, Sergi, D, Capomolla, E, Donzelli, S, Carosi, M, Bagnato, A, Gamucci, T, Tomao, S, Natoli, C, Marchetti, P, Grassadonia, A, Tinari, N, De Tursi, M, Vizza, E, Ciliberto, G, Landi, L, Cappuzzo, F, Barba, M, Blandino, G, Vici, P

“…Abstract Background In Western countries, ovarian cancer (OC) still represents the leading cause of gynecological cancer-related deaths, despite the remarkable…”
Get full text

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis by Gamucci, T., Vaccaro, A., Ciancola, F., Pizzuti, L., Sperduti, I., Moscetti, L., Longo, F., Fabbri, M. A., Giampaolo, M. A., Mentuccia, L., Di Lauro, L., Vici, P.

“…Purpose Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments…”
Get full text

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study by Cazzaniga, M.E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G.V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M.C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M.R., Vici, P., Zambelli, A., Clivio, L., Torri, V., Alù, M., Ancona, C., Andreis, D., Bajardi, E., Benedetto, C., Berardi, R., Bordin, E., Butti, C., Capri, G., Cicchiello, F., Cocciolone, V., Dester, M., D'Onofrio, L., Febbraro, A., Ferrarini, I., Fotia, V., Gervasi, E., Guaitoli, G., Licata, L., Liscia, N., Mentuccia, L., Miraglio, E., Nicolini, M., Paternò, E., Pedani, F., Pellegrini, D., Petrucelli, L., De Laurentiis, M., Pizzuti, L., Pogliani, C., Riva, F.

“…The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET…”
Get full text

Efficacy of pertuzumab in combination with trastuzumab and a taxane in in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study by Mentuccia, L, Gelibter, A, Sperduti, I, D'Onofrio, L, Botticelli, A, Vici, P, Cassano, A, Moscetti, L, Carbognin, L, Graziano, V, Barchiesi, G, Rossi, E, Cursano, M C, Pizzuti, L, Paris, I, Vaccaro, A, Fabbri, A, Rossi, L, Samaritani, R, Sarmiento, R, Gamucci, T

Get full text

The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs) by Gori, S, Turazza, M, Inno, A, Lunardi, G, Moroso, S, La Verde, N, Frassoldai, A, Tarenzi, E, Garrone, O, Vici, P, Laudadio, L, Cretella, E, Foglietta, J, Leonardi, V, Cavanna, L, Barni, S, Marchetti, F, Valerio, M, Carbognin, G, Alongi, F, Fabi, A

Get full text

Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience by Moscetti, L, Vici, P, Gamucci, T, Natoli, C, Cortesi, E, Marchetti, P, Santini, D, Giuliani, R, Sperduti, I, Mauri, M, Pizzuti, L, Mancini, M.L, Fabbri, M.A, Magri, V, Iezzi, L, Sini, V, D'Onofrio, L, Mentuccia, L, Vaccaro, A, Ramponi, S, Roma, C.L, Ruggeri, E.M

“…Abstract Purpose The everolimus and exemestane combination represents a treatment option for the endocrine sensitive metastatic breast cancer (MBC) patients…”
Get full text

1851 Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC) by Moscetti, L, Vici, P, Sperduti, I, Fabbri, M.A, Natoli, C, Mancini, M.L, Sini, V, D'Onofrio, L, Pizzuti, L, Vaccaro, A, Magnolfi, E, Magri, V, Trenta, P, Ramponi, S, Roma, C, Ruggeri, E.M

Get full text

Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort by Barba, M., Sperati, F., Stranges, S., Carlomagno, C., Nasti, G., Iaffaioli, V., Caolo, G., Mottolese, M., Botti, G., Terrenato, I., Vici, P., Serpico, D., Giordano, A., D’Aiuto, G., Crispo, A., Montella, M., Capurso, G., Delle Fave, G., Fuhrman, B., Botti, C., De Placido, S.

“…We investigated pretreatment fasting glucose as a predictor of patients’ important outcomes in breast and colorectal cancers undergoing targeted therapies. In…”
Get full text

Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients by Gamucci, T., Moscetti, L., Mentuccia, L., Pizzuti, L., Mauri, M., Zampa, G., Pavese, I., Sperduti, I., Vaccaro, A., Vici, P.

“…Purpose Diarrhea in relation to the lapatinib–capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment…”
Get full text

1950 Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study by Gamucci, T, Mentuccia, L, Vici, P, Iezzi, L, Sperduti, I, Astone, A, Marchetti, P, Pizzuti, L, Michelotti, A, Sini, V, Cassano, A, Ciancola, F, Quadrini, S, Moscetti, L, Landucci, E, Sergi, D, Magnolfi, E, Natoli, C

Get full text